Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 6,006

Document Document Title
WO/2007/056469A2
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.  
WO/2007/049828A1
Disclosed is a therapeutic agent for unstable cerebrospinal pressure syndrome. It is found that there exists a disease induced by a large fluctuation and instability in a cerebrospinal pressure compared to that in normal persons, and the...  
WO/2007/017511A3
The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1 - R13, A, B, L and i are as defined in the description and the claims. The invention also relates to the use thereof for treating A...  
WO/2006/120133A3
The present invention concerns coloring keratin fibers, especially human hair, with colored metal complexes.  
WO/2007/041258A1
The present invention is directed to benzothiadiazolylphenylalkylamine derivatives of formula (I): or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and ...  
WO/2007/039171A1
The invention relates to 4-oxy-N-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARalpha, PPARdelta and PPARgamma agonist activity. What is ...  
WO/2007/041366A1
The present invention provides compounds of the formula (I), which are activators of glucokinase activity and, thus, may be employed as therapeutic agents for the treatment of glucokinase mediated conditions. Accordingly, the compounds o...  
WO/2007/039175A1
The invention relates to N-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta and PPARgamma agonist activity. What is described are com...  
WO/2007/039173A1
The invention relates to cyclic N-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What ...  
WO/2007/037187A1
A sulfonamide derivative having DP receptor antagonistic activity; and a medicinal composition and a therapeutic agent for allergic diseases which each contains the compound as an active ingredient. The derivative is a compound represent...  
WO/2007/031513A1
The present invention relates to aryloxy substituted phenylamidine derivatives of formula (I) wherein the substituents are as in the description, their process of preparation, their use as fungicide or insecticide active agents, particul...  
WO/2006/105127A3
Compounds, pharmaceutical compositions, kits and methods are provided for use with hydroxysteroid dehydrogenases that comprise a compound selected from the group consisting of: formula (I), wherein the variables are as defined herein.  
WO/2007/026376A2
This invention relates to a process for the preparation and purification of a pure crystalline Hydrochlorothiazide with overall purity 99.9% or greater and single impurity below 0.1%. This is a two step process. In first step crude hydro...  
WO/2007/022845A1
The invention relates to compounds of formula (1) and to the use thereof in organic electroluminescent devices. The compounds of formula (1) are used as host material or as a dopant in the emitting layer and/or as hole transport material...  
WO/2007/017414A1
Dicyanoalkane compounds of formula (I), wherein R1, R2, R3,R4 and A are defined as in the description, or the enantiomers or diastereomers or salts thereof are subject matter of the present invention. Further also processes and intermedi...  
WO/2007/017507A1
The invention relates to the substituted 1,2-ethylenediamines of general formula (I), wherein the groups R1 to R13, A, B, L and i are defined as in the description and the claims. The invention also relates to the use thereof in the trea...  
WO/2007/017511A2
The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1 - R13, A, B, L and i are as defined in the description and the claims. The invention also relates to the use thereof for treating A...  
WO/2007/012724A1
The invention relates to novel antifungal compounds of formula (I). Pharmaceutical antifungal compositions for using in human medicine and veterinary science containing the compound of formula (I), wherein x is a group selected from SO- ...  
WO/2007/010653A1
A salt molten at room temperature that does not contain any organic solvent, excelling in stability; and a display device that is improved in the durability in high-temperature environment by virtue of the use thereof. There is provided ...  
WO/2007/006814A1
The invention provides a compound of general formula (I) wherein the substituents are defined futher in the application, as well as further embodiments hereof described in the attached embodiments. The present invention also provides use...  
WO/2007/007886A1
The problem of the present invention is to provide a useful compound as a glucokinase activating agent, which is the oxime derivative of the formula [I]: wherein Ring A is aryl or heteroaryl; Q is cycloalkyl, heterocycle, alkyl or alkeny...  
WO/2007/005510A1
Certain /V-heteroarylpiperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions medi...  
WO/2006/137490A1
A therapeutic and/or prophylactic agent for restenosis comprising a thiadiazoline derivative represented by the general formula (O) or a pharmaceutically acceptable salt thereof: wherein n represents an integer of 1 to 3; R0 represents a...  
WO2005087752A8
The invention relates to novel aminoalkanol derivatives and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disord...  
WO/2006/133588A1
It has been found that phenylurea compounds, in particular diphenylurea compounds of the formula (I), and pharmaceutically acceptable salts thereof are medicaments for the treatment of neurodegenerative diseases, in particular diseases i...  
WO2006058088A3
In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds and compositions useful in...  
WO2006017409A3
Compounds represented by Formula I: (wherein A, B, D, P, Q, R1, R2, R3, W and Y are described herein) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such a...  
WO2006081034A3
Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hyper-vascularization are provided. ][n a preferred embodiment, modulat...  
WO/2006/122319A2
Compounds, pharmaceutical compositions, kits and methods are provided for use with HDAC that comprise a compound selected from the group consisting of : formula (I) and formula (II) wherein the variables are as defined herein.  
WO/2006/120133A2
The present invention concerns coloring keratin fibers, especially human hair, with colored metal complexes.  
WO/2006/114260A1
The invention provides compounds of formula (I) wherein the substituents are as defined in the specification, to processes for their preparation and corresponding intermediates, and their use as modulators of the mglu5 receptor.  
WO2006084854A3
The present invention relates to 5-imino-5H-[1,2,4]-dithiazol-3-yl-amine and [1,2,4]- dithiazolidine-3,5-diylidene-diamine derivatives as inducers of glutha-thione-S- transferase (GST) and NADPH quinone oxidoreductase (NQO), to methods f...  
WO2006083271A3
The invention provides certain acylthiourea derivatives and pharmaceutically acceptable salts thereof. These compounds possess potent antiviral activity. The invention particularly provides compounds that are potent and/or selective inhi...  
WO2005023182A3
The invention describes novel nitrosated and/or nitrosylated cardiovascular compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated cardiovascular compound, an...  
WO/2006/106960A1
A disulfonyl fluoride compound is easily and efficiently produced through a coupling reaction. The compound is converted to produce a useful compound. A compound (1) in which Y is fluorine is subjected to a photocoupling reaction, while ...  
WO/2006/105127A2
Compounds, pharmaceutical compositions, kits and methods are provided for use with hydroxysteroid dehydrogenases that comprise a compound selected from the group consisting of: formula (I), wherein the variables are as defined herein.  
WO/2006/102760A1
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I); wherein Y, L, Z, W, X, Q, R1, R2 and R3 are as defined in the specification.  
WO/2006/101102A1
Disclosed is an agent for treatment and/or prevention of solid tumors which contains a thiadiazoline derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof. [In the formula, n represents an...  
WO/2006/101104A1
Disclosed is an agent for treatment and/or prevention of arthritis which contains a thiadiazoline derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof. [In the formula, n represents an in...  
WO/2006/101103A1
Disclosed is an agent for treatment and/or prevention of hematopoietic tumor which contains a thiadiazoline derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof. [In the formula, n repres...  
WO2005013914A8
The present invention relates to compounds such as those of formula (I-A) inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and met...  
WO/2006/101105A1
Disclosed is an agent for treatment and/or prevention of psoriasis which contains a thiadiazoline derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof. [In the formula, n represents an in...  
WO/2006/097449A1
New N-hydroxyamides of n-alkyl carboxylic acids omega substituted with suitable tricyclic systems characterised by a central 7-membered ring, having activity as inhibitors of histone deacetylase (HDAC).  
WO/2006/098128A1
There are provided 1,2,3-thiadiazole compounds, or salts thereof, represented by the formula: (I) wherein each of R1, R2, R3, R4 and R5 is H, a halogen, CN, an alkyl, an alkoxyalkyl, an aryl, an arylalkyl, an alkylcarbonyl, etc.; and R6 ...  
WO/2006/098308A1
An anthranilic acid derivative represented by the general formula below or a salt thereof: wherein R1 and R2 independently represent a hydrogen atom or the like; R3 represents a phenyl, cycloalkyl or bicyclic heterocyclic group which may...  
WO2006040113A3
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula I can be used as agrochemical active ingredients ...  
WO/2006/093801A1
Compounds having the formula (I) are hepatitis C (HCV) polymerase inhibitors. Also disclosed are compositions and methods for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employ...  
WO2006055542A3
The invention describes novel diuretic compounds comprising at least one heterocyclic nitric oxide donor group, or pharmaceutically acceptable salts thereof, and novel composition comprising at least one diuretic compound comprising at l...  
WO2006068821A3
The present invention relates to intermediate compounds useful for the preparation of 1,2,5-thiadiazole compounds, including unsymmetrically substituted compounds such as 4-(3-secondary amino-2-hydroxy-propoxy)-1,2,5-thiadiazole compound...  
WO2004087053A3
Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising the formula (I): wherein Q is selected from the group consisting of CO, SO, SO2, or C=NR9; and R1, R...  

Matches 551 - 600 out of 6,006